{"id":657368,"date":"2026-05-06T21:34:01","date_gmt":"2026-05-06T21:34:01","guid":{"rendered":"https:\/\/www.investpr.org\/amgen-puerto-rico-investment-nears-1-billion-with-new-300m-expansion-2\/"},"modified":"2026-07-30T16:32:45","modified_gmt":"2026-07-30T16:32:45","slug":"amgen-puerto-rico-investment-nears-1-billion-with-new-300m-expansion","status":"publish","type":"post","link":"https:\/\/www.investpr.org\/es\/amgen-puerto-rico-investment-nears-1-billion-with-new-300m-expansion\/","title":{"rendered":"La inversi\u00f3n de Amgen Puerto Rico se acerca a los $1,000 millones de d\u00f3lares con una nueva expansi\u00f3n de $300 millones"},"content":{"rendered":"
\n
\"\"<\/figure>\n<\/div>\n\n\n
<\/div>\n\n\n\n

The latest expansion builds on a $650M investment announced in 2025, reinforcing Puerto Rico\u2019s role in U.S. biomanufacturing.<\/em><\/p>\n\n\n\n

Amgen\u2019s Expansion Reinforces Puerto Rico\u2019s Role in U.S. Biomanufacturing<\/strong><\/h2>\n\n\n\n

Amgen\u2019s latest expansion in Puerto Rico marks a significant milestone for the island\u2019s life sciences sector.<\/p>\n\n\n\n

With a new $300 million expansion at its manufacturing facility in Juncos, building on the $650 million investment announced in September 2025, Amgen\u2019s recent investment in Puerto Rico now totals nearly $1 billion.<\/p>\n\n\n\n

For one of the world’s leading biotechnology companies, this level of sustained investment reflects long-term confidence in Puerto Rico as a critical hub for U.S. biomanufacturing. It also underscores a broader reality: companies are scaling in Puerto Rico because it already delivers at global standards.<\/p>\n\n\n\n

A Strategic Investment in Puerto Rico\u2019s Manufacturing Capabilities<\/strong><\/h2>\n\n\n\n

Amgen\u2019s Puerto Rico operations have been a cornerstone of its global manufacturing network since 1992.<\/p>\n\n\n\n

The company\u2019s Juncos facility is one of the largest biologics manufacturing sites in the world, producing medicines distributed to more than 60 countries.<\/p>\n\n\n\n

This latest $300 million investment will enhance advanced manufacturing capabilities, support next-generation technologies, and strengthen production capacity within the United States.<\/p>\n\n\n\n

Strengthening U.S. Supply Chains Through Puerto Rico<\/strong><\/h2>\n\n\n\n

Amgen\u2019s expansion aligns with a broader trend: increasing investment in U.S.-based manufacturing to improve supply chain resilience.<\/p>\n\n\n\n

As Robert A. Bradway, Chairman and Chief Executive Officer at Amgen, stated in the company\u2019s official announcement<\/a>, \u201cBy growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs.\u201d<\/p>\n\n\n\n

Puerto Rico plays a unique role in U.S. manufacturing and supply chain strategy. As a U.S. jurisdiction with decades of pharmaceutical manufacturing experience, the island enables companies to scale operations within a well-established regulatory and operational framework.<\/p>\n\n\n\n

For companies seeking to expand or reshore manufacturing, Puerto Rico provides both speed-to-market and proven reliability.<\/p>\n\n\n\n

Why Biomanufacturing Leaders Choose Puerto Rico<\/strong><\/h2>\n\n\n\n

Puerto Rico continues to attract investment from global life sciences companies due to its strong industrial foundation.<\/p>\n\n\n\n

Key advantages include:<\/p>\n\n\n\n